|
Use of Revlimid as front line med for high risk MDS
Anyone know if any other resources or links that provide information on the effficacy of Revlimid in treating high risk MDS? If Revlimid is the drug of choice for isolated del 5q syndrome (low risk = IPSS score of 0 for cytopenia <anemia> and 0 for marrow blast), given the high risks for high risk MDS mentioned in the study quoted by Birgitta (A majority of patients experienced severe neutropenia and/or thrombocytopenia, and 30 patients (64%) required hospitalization during their treatment course) and given the low success rate (< 21% CR), I am wondering why Revlimid is given for high risk (> 2.0 IPSS) MDS? I have a close relative with RAEB-2 with del 5q taking this drug and wondered if this is common or preferred treatment choice. It may bring up their RBC, but it doesn't appear hopeful to bring up the WBC.
__________________
Rick, close relative has MDS RAEB-2 with pancytopendia, multilineage dysplasia and -5q, on Revlimid
|